Poseida Therapeutics (NASDAQ:PSTX) Earns “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Poseida Therapeutics (NASDAQ:PSTX) in a research note released on Thursday morning, Benzinga reports. They currently have a $20.00 target price on the stock.

Poseida Therapeutics Stock Down 3.5 %

Shares of NASDAQ PSTX opened at $2.45 on Thursday. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.48 and a current ratio of 2.48. Poseida Therapeutics has a 52-week low of $1.83 and a 52-week high of $4.27. The company’s 50 day moving average price is $2.85 and its 200-day moving average price is $2.88. The company has a market capitalization of $237.97 million, a P/E ratio of -2.06 and a beta of 0.51.

Poseida Therapeutics (NASDAQ:PSTX) last released its earnings results on Monday, August 5th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.11. Poseida Therapeutics had a negative net margin of 127.48% and a negative return on equity of 121.01%. The company had revenue of $25.97 million for the quarter, compared to the consensus estimate of $13.75 million. Equities analysts forecast that Poseida Therapeutics will post -1.57 earnings per share for the current year.

Institutional Trading of Poseida Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Bayesian Capital Management LP bought a new stake in Poseida Therapeutics during the 1st quarter valued at $33,000. Marshall Wace LLP bought a new stake in Poseida Therapeutics during the 2nd quarter valued at $31,000. Rothschild Investment LLC bought a new stake in Poseida Therapeutics during the 2nd quarter valued at $35,000. Principal Financial Group Inc. bought a new stake in Poseida Therapeutics during the 2nd quarter valued at $35,000. Finally, Mackenzie Financial Corp bought a new stake in Poseida Therapeutics during the 2nd quarter valued at $51,000. Institutional investors own 46.87% of the company’s stock.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.